Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974099 · ClinicalTrials.gov registry record · Phase 2
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04974099 is a Phase 2 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 6 participants.
The verdict
NCT04974099, a Phase 2 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that formulates a dose based on a patient's blood testing results can better achieve the optimal drug level as compared to standard dosing.
Interventions
- DEVICE RoadMAB precision dashboard
- DRUG Infliximab precision dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04974099
The ClinicalTrials.gov registry entry for NCT04974099 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RoadMAB precision dashboard is the first listed.
NCT04974099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04974099 about?
NCT04974099 is a clinical study titled "Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease". Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determ...
What is the current status of trial NCT04974099?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-10-01. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT04974099?
The interventions under investigation include: RoadMAB precision dashboard (DEVICE), Infliximab precision dosing (DRUG).
Who is sponsoring clinical trial NCT04974099?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.